MX2021015561A - Composiciones farmaceuticas que contienen dapansutrilo. - Google Patents

Composiciones farmaceuticas que contienen dapansutrilo.

Info

Publication number
MX2021015561A
MX2021015561A MX2021015561A MX2021015561A MX2021015561A MX 2021015561 A MX2021015561 A MX 2021015561A MX 2021015561 A MX2021015561 A MX 2021015561A MX 2021015561 A MX2021015561 A MX 2021015561A MX 2021015561 A MX2021015561 A MX 2021015561A
Authority
MX
Mexico
Prior art keywords
treating asthma
administration
dapansutrile
methanesulfonylpropionitrile
directed
Prior art date
Application number
MX2021015561A
Other languages
English (en)
Inventor
Carlo Marchetti
Charles A Dinarello
Original Assignee
Olatec Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Therapeutics Llc filed Critical Olatec Therapeutics Llc
Publication of MX2021015561A publication Critical patent/MX2021015561A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención está dirigida a un método para tratar asma. El método comprende administrar a un sujeto que lo necesite 3-metanosulfonilpropionitrilo (dapansutrilo), o un solvato farmacéuticamente aceptable del mismo, en una cantidad efectiva. La vía de administración preferida es la administración oral o la administración local.
MX2021015561A 2019-06-17 2020-06-15 Composiciones farmaceuticas que contienen dapansutrilo. MX2021015561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962862434P 2019-06-17 2019-06-17
PCT/US2020/037696 WO2020257093A1 (en) 2019-06-17 2020-06-15 Method for treating asthma

Publications (1)

Publication Number Publication Date
MX2021015561A true MX2021015561A (es) 2022-01-24

Family

ID=74040873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015561A MX2021015561A (es) 2019-06-17 2020-06-15 Composiciones farmaceuticas que contienen dapansutrilo.

Country Status (8)

Country Link
US (1) US20220087969A1 (es)
EP (1) EP3983070A4 (es)
JP (1) JP2022536932A (es)
CN (1) CN114007690B (es)
AU (1) AU2020296829A1 (es)
CA (1) CA3141407A1 (es)
MX (1) MX2021015561A (es)
WO (1) WO2020257093A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EP3872070A1 (en) * 2016-04-18 2021-09-01 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity

Also Published As

Publication number Publication date
US20220087969A1 (en) 2022-03-24
EP3983070A4 (en) 2023-04-26
WO2020257093A1 (en) 2020-12-24
CN114007690A (zh) 2022-02-01
EP3983070A1 (en) 2022-04-20
AU2020296829A1 (en) 2022-02-10
CA3141407A1 (en) 2020-12-24
CN114007690B (zh) 2024-03-01
JP2022536932A (ja) 2022-08-22

Similar Documents

Publication Publication Date Title
MX2022005232A (es) Degradadores de moleculas peque?as de helios y procedimientos de uso.
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
WO2020086759A3 (en) Composition and method for treating the lungs
EA201991786A1 (ru) Способы введения некоторых vmat2-ингибиторов
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
MX2020007947A (es) Inhibidores de erbb/btk.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2023008954A (es) Inhibidores de los receptores erbb.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
AR119159A1 (es) Tratamientos de angioedema
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12020551018A1 (en) Oral delivery of glp-1 peptide analogs
MX2021007247A (es) Derivados de rapamicina.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
GEP20247585B (en) Furoindazole derivatives
MX2023001071A (es) Tratamiento de la migraña.
MX2023004149A (es) Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso.
MX2020011453A (es) Combinaciones para tratar el cancer.
MX2020008076A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
TR201721505A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.